Design Therapeutics’s $276 Million Initial Public Offering

Latham & Watkins LLP represented the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Design Therapeutics, Inc.

Design Therapeutics, Inc. executed its initial public offering of 12,000,000 shares of its common stock at a price to the public of US$20 per share. Including the option exercise, the aggregate gross proceeds to Design from the offering were approximately $276.0 million, before deducting the underwriting discounts and commissions and offering expenses.

Goldman Sachs & Co. LLC, SVB Leerink LLC and Piper Sandler acted as joint book-running managers for the offering.

Design Therapeutics is a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by Bay Area partner Brian Cuneo (Picture), Orange County partner Drew Capurro, and San Diego partner Matt Bush, with Orange County associate Mekbeb Hagos. Advice as also provided on benefits and compensation matters by Bay Area partner James Metz, with Bay Area associate Nathaniel Hsieh; on intellectual property matters by Bay Area partner Chris Hazuka, with San Diego associate Robert Yeh and New York associate David Suh; on regulatory matters by Washington, D.C. partner Elizabeth Richards, Bay Area counsel Betty Pang and Heather Deixler, with Washington, D.C. associate Julie Choi Shin; and on tax matters by Bay Area partner Grace Lee, with Orange County associate Janet Hsu.

The Wilson Sonsini Goodrich & Rosati team that advised Design Therapeutics on patent matters related to the IPO includes Michael Hostetler, Uale Taotafa, Katrina Otrubova, and August Renshaw.

Involved fees earner: Matthew Bush – Latham & Watkins; Drew Capurro – Latham & Watkins; Julie Choi Shin – Latham & Watkins; Brian Cuneo – Latham & Watkins; Heather Deixler – Latham & Watkins; Mekbeb Negash Hagos – Latham & Watkins; Christopher Hazuka – Latham & Watkins; Nathaniel Hsieh – Latham & Watkins; Janet Hsu – Latham & Watkins; Grace Lee – Latham & Watkins; James Metz – Latham & Watkins; Betty Pang – Latham & Watkins; Elizabeth Richards – Latham & Watkins; David Suh – Latham & Watkins; Robert Yeh – Latham & Watkins; Michael Hostetler – Wilson Sonsini Goodrich & Rosati; Katrina Otrubova – Wilson Sonsini Goodrich & Rosati; August Renshaw – Wilson Sonsini Goodrich & Rosati; Uale Taotafa – Wilson Sonsini Goodrich & Rosati;

Law Firms: Latham & Watkins; Wilson Sonsini Goodrich & Rosati;

Clients: Design Therapeutics; Goldman Sachs & Co.; Piper Sandler; SVB Leerink LLC;

Author: Martina Bellini